ASCO Annual Meeting: Lung Cancer | Conference

CancerNetwork® sat down with Jonathan Spicer, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about how communication across a multidisciplinary team was necessary to the success of neoadjuvant immunotherapy administration in CheckMate 816.

At ASCO 2021, CancerNetwork® spoke with Stephen Liu, MD, about his research on the ARROW trial and how these results might impact the treatment of patients with RET fusion–positive non–small cell lung cancer who are potential candidates for treatment with pralsetinib.

CancerNetwork® sat down with John Heymach, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk adjuvant immunotherapy for recurrence-free survival in resected non–small cell lung cancer.

At the 2021 ASCO Annual Meeting, Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered non–small cell lung cancer.

Jabbour detailed the importance of managing care in a multidisciplinary setting for patients enrolled in the KEYNOTE-799 trial with stage III NSCLC.

According to data presented at the 2021 ASCO Annual Meeting, patients with crizotinib-refractory ALK-positive non–small cell lung cancer demonstrated long-term response and survival maintenance on brigatinib.

Larotrectinib’s tumor-agnostic indication for NTRK fusion–positive cancers is further validated by data presented at the 2021 ASCO Annual Meeting.

The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Although adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer, the agent did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.

Patients with platinum-pretreated EGFR exon 20 insertion mutation–positive metastatic non–small cell lung cancer experienced antitumor activity with oral TKI mobocertinib, according to results presented at the 2021 ASCO Annual Meeting.